Roche to pay $7.1bn for Telavant to boost its pipeline
Roche Holding AG said Monday it will pay $7.1 billion (CHF6.35 billion) to acquire Telavant Holdings, Inc. in a bid to shore up its pipeline of experimental medicines.
The Swiss pharmaceutical company will gain rights in the US and Japan to develop and market RVT-3101, a promising new therapy for treating inflammatory bowel disease that’s currently undergoing clinical trials. Roche will also provide a near-term milestone payment of $150 million.
The antibody therapy developed by Telavant, which is owned by Roivant Sciences Ltd. and Pfizer Inc., has a novel mode of action that targets both inflammation and fibrosis, giving it potential to be applied in multiple other diseases, Roche said in a statement. In trials so far the drug, which can be delivered at home via injection, has shown it can be used safely by patients.
+ Roche taps AI to find cancer patients after trial success
Roche has come under pressure to improve its pipeline as a windfall of revenue from products used in the Covid-19 pandemic comes to an end. Roche said it will start a global Phase 3 trial for RVT-3101 as soon as possible.
Roche’s shares plunged last week after the company didn’t upgrade its financial targets and reported declining quarterly revenue.
+ Dive into the history of Swiss pharma firms in our long-form featureExternal link
Chief Executive Officer Thomas Schinecker faces a two-pronged challenge: the loss of billions of dollars of pandemic-linked revenue at the same time that some clinical trial stumbles have left many investors questioning the company’s ability to deliver on its highest-profile projects.
Schinecker has pledged to improve the drugmaker’s research and development productivity. Transactions are “not a must” and the existing pipeline and portfolio will be able to fuel growth, Schinecker said in an interview with Bloomberg Television.
“For us it’s important if we look at early-stage deals or late-stage deals that it make sense from a scientific perspective and it has to make sense from a financial perspective,” Schinecker said.
Inflammatory bowel disease is a group of chronic gastrointestinal disorders that affects almost 8 million people worldwide and most of them, some 80%, cannot find lasting treatments.
Telavant was formed in 2022 specifically to develop and commercialize RVT-3101 in the US and Japan. Roivant owns 75% of Telavant and Pfizer owns the rest.
©2023 Bloomberg L.P.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.